Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619158 | 0.79 | PTGS1 (0.39) | CA3CA9CA1CA2 | |
| SCHEMBL1619876 | 0.77 | CA1 (0.35) | TET2CA3CA9CA1CA2 | |
| SCHEMBL4565243 | 0.76 | TET2 (0.35) | TET2CA9CA1CA2LMNA | |
| SCHEMBL30209352 | 0.69 | CA3 (0.40) | CA3CA9CA1CA2ESR1 | |
| SCHEMBL21614392 | 0.69 | CA3 (0.40) | CA3CA9CA1CA2ESR1 | |
| SCHEMBL6760303 | 0.68 | SLC1A3 (0.41) | TET2CA1CA2HSD17B10 | |
| SCHEMBL18066938 | 0.67 | LMNA (0.50) | TET2LMNAHPGDHIF1AHSD17B10 | |
| SCHEMBL20150025 | 0.67 | CA1 (0.47) | TET2CA3CA9CA1CA2 | |
| SCHEMBL17399692 | 0.67 | HSD17B10 (0.36) | TET2CA1CA2LMNAHPGD | |
| Persilic Acid SCHEMBL6930479 | 0.67 | HSD17B10 (0.44) | LMNAHPGDHIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928268-B2 | Process for producing 1,2-dialkoxy-3-fluorobenzene | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100286451-A1 | Process for producing 1,2-dialkoxy-3-fluorobenzene | ASAHI GLASS COMPANY, LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-7786330-B2 | sulfonation, halogenation, deprotection, with 2-fluorophenol as starting material; industrial scale | ASAHI GLASS COMPANY, LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090227817-A1 | Process for producing 1,2-dialkoxy-3-fluorobenzene | ASAHI GLASS COMPANY, LIMITED | 2009-09-10 | — | — | US | disclosed |
| EP-2055692-A1 | PROCESS FOR PRODUCING 1,2-DIALKOXY-3-FLUOROBENZENE | Asahi Glass Co., Ltd. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227817-A1 | Process for producing 1,2-dialkoxy-3-fluorobenzene | HAAO, HDHD5, AFF2 | TET2 489/4885CA3 590/4885CA9 316/4885 |
| US-20100286451-A1 | Process for producing 1,2-dialkoxy-3-fluorobenzene | HAAO, HDHD5, AFF2 | TET2 489/4885CA3 590/4885CA9 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.